Key result
Human atrial appendage-derived cells (hAACs) pre-stimulated with IFNγ strongly inhibited T cell proliferation and reduced pro-inflammatory cytokines, demonstrating enhanced immunomodulatory potential for allogeneic cell therapies.
Why the study?
Rising cardiovascular disease and limited donor heart availability require new therapies, making human atrial appendage-derived cells promising candidates for allogeneic treatment.
Human atrial appendage-derived cells demonstrate low immunogenicity and enhanced immunomodulatory potential in inflammatory environments, supporting their potential use in allogeneic cell therapies for cardiovascular disease.
Supports allogeneic hAAC therapy development in cardiovascular disease; leaves open human translation from animal model data.
Rising numbers of patients with cardiovascular diseases and limited availability of donor hearts require new and improved therapy strategies. Human atrial appendage-derived cells (hAACs) are promising candidates for an allogeneic cell-based treatment. In this study, we evaluated their inductive and modulatory capacity regarding immune responses and underlying key mechanisms in vitro. For this, cryopreserved hAACs were either cultured in the presence of interferon-gamma (IFNγ) or left unstimulated. The expression of characteristic mesenchymal stromal cell markers (CD29, CD44, CD73, CD105, CD166) was revealed by flow cytometry that also highlighted a predominant negativity for CD90. A low immunogeneic phenotype in an inflammatory milieu was shown by lacking expression of co-stimulatory molecules and upregulation of the inhibitory ligands PD-L1 and PD-L2, despite de novo expression of HLA-DR. Co-cultures of hAACs with allogeneic peripheral blood mononuclear cells, proved their low immunogeneic state by absence of induced T cell proliferation and activation. Additionally, elevated levels of IL-1β, IL-33 and IL-10 were detectable in those cell culture supernatants. Furthermore, the immunomodulatory potential of hAACs was assessed in co-cultures with αCD3/αCD28-activated peripheral blood mononuclear cells. Here, a strong inhibition of T cell proliferation and reduction of pro-inflammatory cytokines (IFNγ, TNFα, TNFβ, IL-17A, IL-2) were observable after pre-stimulation of hAACs with IFNγ. Transwell experiments confirmed that mostly soluble factors are responsible for these suppressive effects. We were able to identify indolamin-2,3-dioxygenase (IDO) as a potential key player through a genome-wide gene expression analysis and could demonstrate its involvement in the observed immunological responses. While the application of blocking antibodies against both PD-1 ligands did not affect the immunomodulation by hAACs, 1-methyl-L-tryptophan as specific inhibitor of IDO was able to restore proliferation and to lower apoptosis of T cells. In conclusion, hAACs represent a cardiac-derived mesenchymal stromal-like cell type with a high potential for the application in an allogeneic settings, since they do not trigger T cell responses and even increase their immunomodulatory potential in inflammatory environments.
No takes yet. Share an insight, caveat, or question.
Diedrichs et al. (2019) studied Cardiovascular diseases (in vitro cell therapy model) (n=8). Interferon-gamma (IFNγ) stimulation of human atrial appendage-derived cells (hAACs) vs. Unstimulated hAACs was evaluated on T cell proliferation and activation. Human atrial appendage-derived cells (hAACs) pre-stimulated with IFNγ strongly inhibited T cell proliferation and reduced pro-inflammatory cytokines, demonstrating enhanced immunomodulatory potential for allogeneic cell therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: